1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies

BACKGROUND: Cefiderocol (CFDC) is a novel siderophore cephalosporin developed to treat serious carbapenem-resistant (CR) Gram-negative (GN) infections. METHODS: In CREDIBLE-CR (NCT02714595), adults with serious infections caused by CR GN pathogens received CFDC 2 g, q8h, 3-h infusion, or best availa...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemura, Miki, Yamano, Yoshinori, Matsunaga, Yuko, Ariyasu, Mari, Echols, Roger, Den Nagata, Tsutae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776663/
http://dx.doi.org/10.1093/ofid/ofaa439.1450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776663/
http://dx.doi.org/10.1093/ofid/ofaa439.1450

Ejemplares similares